Skip to main content
English version. Prefer Traditional Chinese? Switch to Chinese
Dermatology Patient-Education Notes

From the clinic toyour everyday skin.

A resident dermatologist's field notes — patient questions, new evidence, and the daily basics of caring for your skin.

Quick find by topic
AllAcneEczemaPerioral dermatitisToenail disordersOral mucosaBiologic safetyDupilumabPediatric EczemaMelasmaSunscreenRosaceaPsoriasisHair LossAlopeciaUrticariaTineaWartsShinglesVitiligoHSBiologicsLaser dermatologyNHI rules
Articles

What clinic doesn't have time to explain.

Latest ResearchHS biologic (bimekizumab)

Does bimekizumab work for hidradenitis suppurativa? A critical appraisal of the BE-HEARD I/II phase III trials

HS is hard to treat. Bimekizumab inhibits both IL-17A and IL-17F; in the BE-HEARD I/II phase III trials about half reached HiSCR 50 at week 16, beating placebo, with efficacy comparable to adalimumab and secukinumab. A 2026 BJD critical appraisal also flags a 31% placebo response, common candida infections, and falling long-term retention.

→
Latest ResearchNail psoriasis therapy

How is nail psoriasis treated? Topical, intralesional, and laser-assisted delivery — a 2026 JAAD editorial review

Topicals often fail in nail psoriasis — the drug can not cross the thick nail plate. A 2026 JAAD editorial (Elston) reviews vitamin D ointments, topical MTX + CO2 laser, and intralesional injection, marking the Taiwan NHI vs self-pay divide; injection is an advanced, self-pay option for refractory disease.

→
Latest ResearchJAKi switching

Does switching JAK inhibitors work for alopecia areata? Real-world data from 108 switches (JAAD 2026)

JAAD 2026 multicenter retrospective (n=108): 48.8% reached SALT≤20 on a second JAK inhibitor, 52.4% on a third. Responding to the first was the strongest predictor (OR 3.33). Covers switch paths, safety, and Taiwan drug names.

→
K+!
Latest ResearchSpironolactone safety

Is spironolactone safe in dermatology? JAAD 2026: hyperkalemia in women ≥45 and combination LDOM prescribing

Two June-2026 JAAD studies: hyperkalemia 10.1% overall in women ≥45 (28.1% with age ≥65 + comorbidity), but 97.5% mild and 62.5% needed no change. Simultaneous LDOM start cut hypertrichosis 64.8%. Stratified monitoring + Taiwan off-label context.

→
Latest ResearchPhotodynamic therapy

Photodynamic Therapy (PDT) Complete Guide — from AK and BCC to acne, synthesis of two 2026 JAAD Reviews

Synthesis of two 2026 JAAD CME Reviews: PDT triad (PS + light + oxygen) → selective ROS damage. LoE IA indications: AK (77-89%), superficial BCC (92-97%), Bowen disease, acne (matches isotretinoin, lower recurrence). 7 patient FAQs + 12 indications dual-track + 5 mechanism/evidence figures.

→